Table 2.
Characteristics of 117 patients stratified by chemotherapeutic regimen.
| Total N = 117 |
PF∗
(percentage) n = 50 |
Taxane-incorporated CCRT∗∗
(percentage) n = 67 |
P value | |
|---|---|---|---|---|
| Age | ||||
| <60 y | 66 | 19 (38.0) | 47 (70.1) | 0.001 |
| ≥60 y | 51 | 31 (62.0) | 20 (29.9) | |
| Gender | ||||
| Male | 107 | 46 (92.0) | 67 (91.0) | 0.565 |
| Female | 10 | 4 (8.0) | 6 (9.0) | |
| Site | ||||
| Upper thoracic | 16 | 6 (12.0) | 10 (14.9) | 0.171 |
| Middle thoracic | 47 | 25 (50.0) | 22 (32.8) | |
| Lower thoracic | 54 | 19 (38.0) | 35 (52.2) | |
| Op. complication | ||||
| No | 61 | 21 (42.0) | 40 (59.7) | 0.058 |
| Yes | 56 | 29 (58.0) | 27 (40.3) | |
| CCRT complication | ||||
| No | 77 | 33 (66.0) | 44 (65.78) | 0.970 |
| Yes | 40 | 17 (34.0) | 23 (34.3) | |
| Progression∗∗∗ | ||||
| Nonprogression | 45 | 11 (22.0) | 34 (50.7) | 0.002 |
| Disease progression | 72 | 39 (78.0) | 33 (49.3) |
P value from χ 2 test or Fisher's exact test where the value is <0.05.
∗PF: cisplatin and 5-fluorouracil.
∗∗Taxane-incorporated CCRT: modified TPFL or TP-HDFL and then neoadjuvant CCRT (TP regimen), or the standard neoadjuvant CCRT with TP regimen.
∗∗∗The patients with postoperative mortality or cancer recurrence.